Chronic Airways Assessment Test (CAAT)
Chronic Airways Assessment Test: A unified tool for assessing chronic airway diseases
CAAT can now be used for assessing respiratory health status in people with asthma, not just COPD
A simple and standardized health status measure
A standardized, easy to administer, health status measure for use across obstructive lung diseases.
Structure and components of the CAAT
8-items assessing aspects of disease relevant to patients.
Development and validation
The COPD assessment test (CAT) and the Chronic Airways Test (CAAT) were developed by an interdisciplinary group of international experts with support from GSK.
CAT and CAAT activities are monitored by a supervisory council that includes independent experts, one of which is chair of the council.
CAT, COPD Assessment Test, CAAT, Chronic Airways Assessment Test and the CAT logo are trademarks of the GSK group of companies.
Implementation and resources
Scan the QR code for the CAAT User Guide.
Documents for download
Read more details at
Fecha de publicación
September 2025
Categorías asociadas al artículo
Noticias relacionadas

Respiratory Preceptorship 2026 to be held at Món Clínic Barcelona
Explore the Respiratory Preceptorship 2026 at Món Clínic Barcelona, featuring expert sessions on asthma, COPD, pulmonary rehabilitation and respiratory medicine.

Transforming COPD by Addressing Two Key Bottlenecks: Diagnosis and Clinical Control During Follow-up
Learn why earlier COPD diagnosis and better clinical control during follow-up are essential to reduce exacerbations, improve quality of life and optimise patient outcomes.

Biomarkers of Pre-COPD Lung Function Trajectories in Middle Age: A Prospective Study From 1st to 6th Decade
Blood biomarkers including CC16, sRAGE and SPD identify pre-COPD lung function trajectories and may improve early COPD risk detection and prevention.

Año SEPAR de la Vía Aérea 2026/27: una iniciativa para mejorar la salud respiratoria
Descubre el Año SEPAR de la Vía Aérea 2026/27 y sigue sus contenidos sobre asma, EPOC y bronquiectasias para mejorar la salud respiratoria.

THE P4COPD STUDY: RATIONALE, GOALS AND STUDY DESIGN Prediction, Prevention, Personalized and Precision management of COPD in young adults
El estudio P4COPD investiga cómo predecir, prevenir y personalizar el manejo de la pre-EPOC en adultos jóvenes mediante medicina de precisión y biomarcadores.

Jornada RespirAP 2026: conexión entre Atención Primaria y Neumología para mejorar la atención al paciente respiratorio
Jornada RespirAP 2026 con las principales novedades en enfermedades respiratorias, Atención Primaria y Neumología presentadas por expertos nacionales.
Imagen obtenida de la presentación